PRECIGEN INC (PGEN)
US74017N1054 - Common Stock
PRECIGEN INC
NASDAQ:PGEN (4/18/2024, 7:13:55 PM)
After market: 1.34 +0.02 (+1.52%)1.32
+0.01 (+0.76%)
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 209 full-time employees. The company went IPO on 2013-08-08. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. Its lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. AG019 ActoBiotics is a disease-modifying approach to induce antigen-specific immune tolerance to prevent, delay or reverse type-1 diabetes (T1D).
Company Info
PRECIGEN INC
20374 Seneca Meadows Parkway
Germantown MARYLAND 20876
P: 13015569900
CEO: Helen Sabzevari
Employees: 209
Website: https://precigen.com/
PGEN News
21 days ago - Precigen, Inc.Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
a month ago - InvestorPlacePGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023PGEN stock results show that Precigen missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
a month ago - BusinessInsiderPGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023InvestorPlace - Stock Market News, Stock Advice & Trading Tips Precigen (NASDAQ:PGEN) just reported results for the fourth quarter of 2023.Pre...
a month ago - Precigen, Inc.Precigen Reports Full Year 2023 Financial Results and Business Updates– Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an...
a month ago - Precigen, Inc.Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
a month ago - Precigen, Inc.Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
PGEN Twits
Here you can normally see the latest stock twits on PGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
